Novo Nordisk A/S Company Profile (NYSE:NVO)

About Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S logoNovo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NYSE:NVO
  • CUSIP: N/A
  • Web:
  • Market Cap: $104.02 billion
  • Outstanding Shares: 2,495,800,000
Average Prices:
  • 50 Day Moving Avg: $38.81
  • 200 Day Moving Avg: $35.72
  • 52 Week Range: $30.89 - $57.44
  • Trailing P/E Ratio: 18.57
  • Foreward P/E Ratio: 16.67
  • P/E Growth: 1.95
Sales & Book Value:
  • Annual Revenue: $16.57 billion
  • Price / Sales: 6.28
  • Book Value: $2.37 per share
  • Price / Book: 17.59
  • Annual Dividend: $1.03
  • Dividend Yield: 2.7%
  • EBIDTA: $7.73 billion
  • Net Margins: 33.97%
  • Return on Equity: 90.61%
  • Return on Assets: 42.44%
  • Current Ratio: 1.26%
  • Quick Ratio: 0.96%
  • Average Volume: 2.31 million shs.
  • Beta: 0.83
  • Short Ratio: 0.69

Frequently Asked Questions for Novo Nordisk A/S (NYSE:NVO)

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared an annual dividend on Tuesday, February 7th. Investors of record on Monday, March 27th will be paid a dividend of $0.6634 per share on Tuesday, April 4th. This represents a yield of 1.99%. The ex-dividend date is Thursday, March 23rd. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its Board of Directors has authorized a share buyback program on Thursday, April 6th 2017, which authorizes the company to repurchase shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 18.9% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Friday, April, 29th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.53 by $0.02. The company earned $4.02 billion during the quarter, compared to the consensus estimate of $4.07 billion. Novo Nordisk A/S had a net margin of 33.97% and a return on equity of 90.61%. View Novo Nordisk A/S's Earnings History.

Where is Novo Nordisk A/S's stock going? Where will Novo Nordisk A/S's stock price be in 2017?

14 brokers have issued 1-year price objectives for Novo Nordisk A/S's stock. Their predictions range from $57.00 to $57.00. On average, they anticipate Novo Nordisk A/S's share price to reach $57.00 in the next twelve months. View Analyst Ratings for Novo Nordisk A/S.

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:

  • Goran A. Ando M.D., Chairman of the Board
  • Lars Fruergaard Joergensen, President, Chief Executive Officer
  • Jeppe Christiansen, Vice Chairman of the Board
  • Jesper Brandgaard, Chief Financial Officer, Executive Vice President
  • Maziar Mike Doustdar, Executive Vice President, International Operations
  • Mads Krogsgaard Thomsen, Chief Science Officer, Executive Vice President
  • Henrik Ehlers Wulff, Executive Vice President, Product Supply
  • Doug Langa, Senior Vice President, Head of North America Operations, President of Novo Nordisk Inc.
  • Liselotte Hyveled, Director, Employee Representative
  • Kasim Kutay, Director

Who owns Novo Nordisk A/S stock?

Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Loomis Sayles & Co. L P (0.76%), Renaissance Technologies LLC (0.66%), Bank of America Corp DE (0.48%), Fisher Asset Management LLC (0.41%), Folketrygdfondet (0.24%) and State Street Corp (0.22%). View Institutional Ownership Trends for Novo Nordisk A/S.

Who sold Novo Nordisk A/S stock? Who is selling Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., JPMorgan Chase & Co., FMR LLC, Capital Fund Management S.A., Fayez Sarofim & Co, Fisher Asset Management LLC, Stock Yards Bank & Trust Co. and Atwood & Palmer Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

Who bought Novo Nordisk A/S stock? Who is buying Novo Nordisk A/S stock?

Novo Nordisk A/S's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Karp Capital Management Corp, Sustainable Growth Advisers LP, River Road Asset Management LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and Bank of America Corp DE. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy Novo Nordisk A/S stock?

Shares of Novo Nordisk A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of Novo Nordisk A/S stock can currently be purchased for approximately $41.68.

MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
Community Ranking:  1.4 out of 5 ()
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novo Nordisk A/S (NYSE:NVO) (?)
Ratings Breakdown: 4 Sell Ratings, 6 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $57.00 (36.76% upside)

Analysts' Ratings History for Novo Nordisk A/S (NYSE:NVO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
1/3/2017JPMorgan Chase & Co.DowngradeNeutral -> UnderweightN/AView Rating Details
12/20/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
12/1/2016Credit Suisse Group AGReiterated RatingHoldN/AView Rating Details
10/31/2016DNB MarketsDowngradeBuy -> HoldN/AView Rating Details
10/31/2016Citigroup IncDowngradeBuy -> NeutralN/AView Rating Details
10/28/2016Bank of America CorpDowngradeNeutral -> UnderperformN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/13/2016BNP ParibasUpgradeNeutral -> OutperformN/AView Rating Details
9/13/2016Pacific CrestUpgradeNeutral -> OutperformN/AView Rating Details
9/12/2016Deutsche Bank AGUpgradeHold -> BuyN/AView Rating Details
9/1/2016Morgan StanleyDowngradeOverweight -> Equal WeightN/AView Rating Details
6/28/2016Goldman Sachs Group IncDowngradeConviction-Buy -> BuyN/AView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> BuyN/AView Rating Details
9/21/2015SwedbankUpgradeStrong-BuyN/AView Rating Details
8/28/2015Leerink SwannInitiated CoverageMarket Perform$56.00N/AView Rating Details
8/10/2015Main First Bank AGDowngradeHoldN/AView Rating Details
(Data available from 5/30/2015 forward)


Earnings History for Novo Nordisk A/S (NYSE:NVO)
Earnings by Quarter for Novo Nordisk A/S (NYSE:NVO)
Earnings History by Quarter for Novo Nordisk A/S (NYSE NVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/29/2016Q1$0.53$0.55$4.07 billion$4.02 billionViewListenView Earnings Details
10/29/2015Q3$0.47$0.49$4.03 billion$3.99 billionViewN/AView Earnings Details
4/30/2015Q1$0.39$0.45$25.13 billion$25.20 billionViewN/AView Earnings Details
1/30/2015Q4$2.48$0.38$24.67 billion$24.59 billionViewN/AView Earnings Details
8/7/2014Q2$2.60$0.48$21.86 billion$21.63 billionViewN/AView Earnings Details
5/1/2014Q1$0.44$0.45$20.83 billion$20.30 billionViewN/AView Earnings Details
1/28/2014Q413$0.42ViewN/AView Earnings Details
10/31/2013Q1$12.11$2.20$21.04 billion$20.51 billionViewN/AView Earnings Details
8/8/2013Q1$11.97$12.45$21.09 billion$21.38 billionViewN/AView Earnings Details
5/1/2013$10.67$10.98$19.73 billion$19.98 billionViewN/AView Earnings Details
1/31/2013$9.77$10.53$20.83 billion$20.96 billionViewN/AView Earnings Details
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novo Nordisk A/S (NYSE:NVO)
2017 EPS Consensus Estimate: $2.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.52$0.52$0.52
Q2 20171$0.52$0.52$0.52
Q3 20171$0.53$0.53$0.53
Q4 20171$0.55$0.55$0.55
(Data provided by Zacks Investment Research)


Current Dividend Information for Novo Nordisk A/S (NYSE:NVO)
Most Recent Dividend:4/4/2017
Annual Dividend:$1.03
Dividend Yield:2.47%
Dividend Growth:31.50% (3 Year Average)
Payout Ratio:46.19% (Trailing 12 Months of Earnings)
45.58% (Based on This Year's Estimates)
41.20% (Based on Next Year's Estimates)
Track Record:20 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Novo Nordisk A/S (NYSE:NVO)

Dividend History by Quarter for Novo Nordisk A/S (NYSE NVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership Percentage: 6.65%
Insider Trades by Quarter for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)
Insider Trades by Quarter for Novo Nordisk A/S (NYSE:NVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.28$31,876.98
(Data available from 1/1/2013 forward)


Headline Trends for Novo Nordisk A/S (NYSE:NVO)
Latest Headlines for Novo Nordisk A/S (NYSE:NVO)
DateHeadline logoNovo Nordisk A/S: Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label - May 27 at 7:18 PM logoNovo Nordisk: The Worst Is Over - Seeking Alpha - May 24 at 10:23 AM logoNevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices - May 22 at 6:11 PM logoThe 3 Best Obesity-Drug Stocks to Buy in 2017 - May 19 at 11:43 AM logoChange in composition of the Board of Directors of Novo Nordisk A/S - May 16 at 6:39 PM logoNovelion CEO quits Novo Nordisk board due to NASH conflict - May 16 at 6:39 PM logoNovo Nordisk A/S (NVO) Given Consensus Rating of "Hold" by Brokerages - May 16 at 10:31 AM logoNovo Nordisk A/S (NVO) Earns Daily Coverage Optimism Score of 0.24 - May 12 at 12:57 AM logoNovo Nordisk CEO: Most growth coming from organic pipelin... - May 10 at 11:59 AM logoNovo Nordisk Sees More Competition in U.S. Drug Prices - May 10 at 11:59 AM logoNovo Nordisk A/S (NVO) Earns Coverage Optimism Rating of 0.28 - May 8 at 11:44 PM logoNovo Nordisk A/S (NVO) Lifted to "B-" at TheStreet - May 6 at 11:14 PM logoSomewhat Favorable Media Coverage Somewhat Likely to Affect Novo Nordisk A/S (NVO) Stock Price - May 4 at 9:34 PM logoNovo Needs New Blood Despite Q1 Relief - Seeking Alpha - May 4 at 7:05 PM logoNovo Nordisk: No Rush To Jump In After Q1 2017 Results - Seeking Alpha - May 4 at 7:05 PM logoNovo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y - May 4 at 7:05 PM logoNovo Nordisk A/S Jumps Over Its Lowered Bar - May 4 at 7:05 PM logoNovo Nordisk A/S: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017 - May 4 at 1:08 AM logoNovo Nordisk Struggles to Raise Prices in Face of Weakening British Pound - May 4 at 1:08 AM logoDrugmaker Novo Nordisk beats Q1 operating profit forecast, nudges up FY outlook range - May 4 at 1:08 AM logoNovo's Legal Challenges Mount as States Query Insulin Prices - May 4 at 1:08 AM logoDrugmaker Novo Nordisk nudges up full-year profit outlook after Q1 beat - May 4 at 1:08 AM logoNovo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost - May 4 at 1:08 AM logoNovo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United States - May 4 at 1:08 AM logoNovo Nordisk beats 1Q profit forecasts - Yahoo Finance - May 3 at 8:07 PM logoNovo Nordisk A/S (NVO) Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 3 at 8:07 PM logo[$$] Novo Nordisk Narrows Guidance as Earnings Beat Forecasts - May 3 at 8:07 PM logo[$$] Novo Nordisk Struggles to Raise Prices - May 3 at 8:07 PM logoNovo Nordisk beats 1Q profit forecasts - May 3 at 5:16 AM logoNovo Nordisk A/S (NVO) Receiving Positive Press Coverage, Report Finds - May 1 at 12:16 PM logoNovo Settles U.S. Probe of Kickbacks, Disguised Salespeople - April 28 at 7:56 PM logoNovo Nordisk has been accused of engaging in a 'white coat marketing scheme' to sell diabetes drugs - April 28 at 7:56 PM logoBRIEF-Novo Nordisk: FDA approves label update for obesity drug Saxenda - April 27 at 7:25 PM logoZacks Investment Research Upgrades Novo Nordisk A/S (NVO) to Hold - April 25 at 1:38 PM logoNovo Nordisk A/S (NVO) Given Daily Coverage Optimism Score of -0.14 - April 24 at 2:04 PM logoNVO December 15th Options Begin Trading - April 24 at 12:47 PM logoBRIEF-Xoma receieves notice to terminate license agreement from Novo Nordisk - April 21 at 6:48 PM logoNovo Nordisk A/S (NVO) Given Consensus Recommendation of "Hold" by Analysts - April 21 at 11:54 AM logoZacks Investment Research Lowers Novo Nordisk A/S (NVO) to Sell - April 19 at 12:05 PM logoNovo Nordisk A/S (NVO) Getting Somewhat Favorable News Coverage, Analysis Shows - April 18 at 8:53 PM logoCitigroup Commercial Mortgage Trust 2017-P7 -- Moody's Assigns Definitive Ratings to Nine CMBS Classes of Citigroup Commercial Mortgage Trust 2017-P7 - April 18 at 6:18 PM logoNovo Nordisk Invites the Community to Unmask Everyday Heroes in Recognition of World Hemophilia Day - April 17 at 9:50 AM logoNovo Nordisk A/S (NVO) Receiving Somewhat Positive Media Coverage, Analysis Finds - April 14 at 11:29 PM logoDenmark's Novo A/S Ups Synlab Stake to 20 Percent Before Possible IPO - April 12 at 11:01 AM logoNovo Nordisk A/S (NVO) Upgraded to "Hold" at Zacks Investment Research - April 11 at 12:22 PM logoNovo Nordisk A/S : NVO-US: Dividend Analysis : March 27th, 2017 (record date) : By the numbers : April 10, 2017 - April 10 at 6:30 PM logo[$$] The Charms of Bayer and Novo Nordisk - April 8 at 12:16 PM logoNovo Nordisk A/S (NVO) Lowered to "Reduce" at HSBC Holdings plc - April 7 at 8:21 PM logoAiling Novo Seeks Cure With Diabetes Drug Targeting Fat Too - April 7 at 11:38 AM logoNovo Nordisk A/S (NVO) to Buyback Stock - April 6 at 4:19 PM



Novo Nordisk A/S (NVO) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by Staff